CN105343110B - A kind of periplogenin and its derivative are used to prevent and treat the application of skin hyperplasia disease - Google Patents
A kind of periplogenin and its derivative are used to prevent and treat the application of skin hyperplasia disease Download PDFInfo
- Publication number
- CN105343110B CN105343110B CN201510811907.0A CN201510811907A CN105343110B CN 105343110 B CN105343110 B CN 105343110B CN 201510811907 A CN201510811907 A CN 201510811907A CN 105343110 B CN105343110 B CN 105343110B
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- hydroxyl
- compound
- oxygroup
- periplogenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
- C07J19/005—Glycosides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the applications that a kind of periplogenin and its derivative are used to prevent and treat skin hyperplasia disease, the special periplogenin and its derivative are as the application in preparation prevention and treatment skin hyperplasia disease medicament composition, capsule, tablet, emulsion, creme, gelling agent or paste is made in the pharmaceutical composition, and the weight content containing periplogenin and its derivative is 1~99%.Periplogenin and its derivative, which pass through, inhibits application on human skin abnormal proliferative cell proliferation, significant effect, and safety is good.
Description
Technical field
The invention belongs to biomedicine technical fields, and in particular to a kind of periplogenin and its derivative are for preventing and treating skin
The application of proliferative disease.
Background technique
Skin hyperplasia disease refer to Skin Cell including, the lower hyperplasia of prostate carried out of extrinsic factor stimulation, it is included
Disease has psoriasis, verruca vulgaris, periungual wart, seborrheic keratosis, verruca plana, plantar wart, melanotic nevus, senile plaque and hemangioma,
Site of pathological change is mainly in four limbs, and secondly in face and trunk, average every has skin lesion at 3.Skin hyperplasia disease is generally not
Health can be caused to seriously endanger, but pain, appearance damage, or even action obstacle can be caused, patient is generated very
Big puzzlement (Joseph S.Mclaughlin, Adam B.Shafritz, MD.Cutaneous Warts [J] .JHS, 2011,
36:342-344.).The skin hyperplasia disease incidence age was mainly distributed between 11-50 years old, very universal to the harm of group.
Currently, China treatment psoriasis key agents have methotrexate (MTX), tretinoin, cyclosporin, glucocorticoid,
Tar, anthrol, salazosulfamide class, vitamin D 3 analogs, tazarotene, Etanercept, Infliximab or dexamethasone
Deng.But there are many disadvantages for these drugs：Keep epidermis and the corium of skin thinning and cause the toxic side effects such as telangiectasis；
The symptom of progress phase patient can only be quickly controlled, the paracmasis of patient cannot be effectively extended；Biological agent such as Etanercept and English
Husband's benefit former times etc. is expensive.The major technique for treating psoriasis has the therapies such as laser surgey, liquid nitrogen frozen, but operative treatment period
It is long, there is injury to skin, and there are scars.Traditional Chinese medicine treatment psoriasis is with a long history, mainly there is tripterygium wilfordii, Kunming mountain and sea
Chinese bush cherry, Indiginis Naturalis Pill, YUJIN YINXIE PIAN, the spirit of silver bits, Granula Yinxie etc., these Chinese medicines have the improvement state of an illness, extension paracmasis, expense low
The features such as honest and clean and Small side effects, but curative effect is more slow, and cure rate is low, high recurrence rate.Therefore current traditional Chinese and western medicine is cured the disease and is not all had
Effective in cure exact drug.
Periplogenin (periplogenin) is a kind of cardiac glycosides that extracting and developing, purifying obtain from periploca spium root skin,
Molecular formula C23H34O5, molecular weight 390.5131, No. CAS is 514-39-6, there is heart tonifying, anti-inflammatory and antitumor etc. pharmacological actions, right
The kinds of tumor cells of in vitro culture such as MCF-7 Human Breast Cancer Cells, human gastric cancer and SGC-7901 cell, people
Lung cancer A549 cell, human colon carcinoma LOVO cell, human hepatoma HepG2 cell all have significant cytotoxicity, and half inhibits dense
Degree has apparent time and dose dependent between 0.146-1.150 μ g/m l, and tumor animal experiment shows thick stick
Willow aglycon can significantly extend the time-to-live of lotus ascites tumor mouse, inhibit growth (Han Yubo, Zhao Aiguo the periplocoside of solid tumor
The antitumor action Chinese children blood and tumour will .2008 of member, 13 (1)：1-5.).In short, in the past for periplogenin
The understanding of pharmacological action is concentrated mainly on its antitumor action and anti-inflammatory effect, but present invention discover that periplogenin and its derivative
It is inhibited to the proliferation of application on human skin abnormal proliferative cell, and to inderal induction cavy psoriasis model have compared with
Good therapeutic effect, but to subcutaneous connective tissue cell A9, then unrestraint is acted on, thus can treat skin hyperplasia disease.
Summary of the invention
The purpose of the present invention is to provide a kind of periplogenin and its new medical usages of derivative, and being used to prepare can answer
For treating the preparation of skin hyperplasia disease.
The present invention is realized especially by following technical scheme：
The present invention provides the applications that a kind of periplogenin and its derivative are used to prevent and treat skin hyperplasia disease.
Periplogenin and its derivative of the present invention are as in preparation prevention and treatment skin hyperplasia disease medicament composition
Application, the periplogenin and its derivant structure general formula are as follows：
Wherein R1For hydroxyl, R2For hydrogen, R3For methyl, R4For hydrogen, R5For hydrogen；
Or R1For hydroxyl, R2For hydroxyl, R3For hydroxyl, R4For hydroxyl, R5For hydrogen；
Or R1For hydroxyl, R2For hydrogen, R3For hydroxyl, R4For hydrogen, R5For hydrogen；
Or R1For hydroxyl, R2For hydrogen, R3For carboxyl, R4For hydrogen, R5For hydrogen；
Or R1For acetoxyl group, R2For hydrogen, R3For hydroxyl, R4For hydrogen, R5For hydrogen；
Or R1For acetoxyl group, R2For hydrogen, R3For hydroxyl, R4For hydrogen, R5For hydrogen；
Or R1For acetoxyl group, R2For hydrogen, R3For methyl, R4For hydrogen, R5For hydrogen；
Or R1For acetoxyl group, R2For hydrogen, R3For aldehyde radical, R4For hydrogen, R5For hydrogen；
Or R1For acetoxyl group, R2For acetoxyl group, R3For acetoxyl group, R4For acetoxyl group, R5For hydrogen；
Or R1For acetoxyl group, R2For hydroxyl, R3For acetoxyl group, R4For acetoxyl group, R5For hydrogen；
Or R1For acetoxyl group, R2For hydrogen, R3For acetoxyl group, R4For hydrogen, R5For hydrogen；
Or R1For acetoxyl group, R2For hydroxyl, R3For hydroxyl, R4For acetoxyl group, R5For hydrogen；
Or R1For 6- methyl -5- hydroxyl -4- methoxyl group pyrans oxygroup, R2For hydrogen, R3For aldehyde radical, R4For hydrogen, R5For hydrogen；
Or R1For 6- deoxidation-α-L- sandlwood glycosyloxy, R2For hydroxyl, R3For hydroxyl, R4For hydroxyl, R5For hydrogen；
Or R1For 2,6- deoxidation -3- methoxyl group-β-D- core-own pyrans glycosyloxy, R2For hydrogen, R3For aldehyde radical, R4For hydrogen, R5For
Hydrogen；
Or R1For 6- deoxidation-α-L- sandlwood glycosyloxy, R2For hydrogen, R3For aldehyde radical, R4For hydrogen, R5For hydrogen；
Or R1For 6- methyl -3,4,5- trihydroxy pyrans oxygroup, R2For hydrogen, R3For aldehyde radical, R4For hydrogen, R5For hydrogen；
Or R1For 6- methyl -3,4,5- trihydroxy pyrans oxygroup, R2For hydrogen, R3For aldehyde radical, R4For hydrogen, R5For hydroxyl；
Or R1For 6- methyl -3,5- dihydroxy -4- methoxyl group pyrans oxygroup, R2For hydrogen, R3For methyl, R4For hydrogen, R5For hydrogen；
Or R1For 6- deoxidation -2,3- dimethoxy-D- glucopyra glycosyloxy, R2For hydrogen, R3For aldehyde radical, R4For hydrogen, R5For
Hydrogen；
Or R1For 2,4- diethyl acyl-oxygen -6- deoxidation -3- methoxyl group-D- galactopyranosyl glycosyloxy, R2For hydrogen, R3For methyl, R4
For hydrogen, R5For hydrogen；
Or R1For 4- acetyl oxygen -6- deoxidation -2,3- dimethoxy-D- glucopyra glycosyloxy, R2For hydrogen, R3For aldehyde radical, R4
For hydrogen, R5For hydrogen；
Or R1For 6- oxygen-(6'- deoxidation -2', 3'- dimethoxy-D- galactopyranose)-D- glucopyra glycosyloxy, R2For
Hydrogen, R3For aldehyde radical, R4For hydrogen, R5For hydrogen；
Or R1For 6- methyl -3,4,5- trihydroxy pyrans oxygroup, R2For hydroxyl, R3And R4For five yuan of lactones, R5For hydrogen；
Or R1For benzoyloxy, R2For hydrogen, R3For methoxycarbonyl group, R4For hydrogen, R5For hydrogen.
Periplogenin and its derivative of the present invention include periplogenin, Kombe-Strophanthin, 17 α-strophanthidol, 17 α-
3,5,14- trihydroxy -20 (22)-enol -19- carboxylic acid, 17 α -3- acetyl oxygen -5,14,19- trihydroxies -20 (22)-enol, 3-
Acetyl oxygen -5,14- dihydroxy -20 (22)-enol, -17 α of 3- acetyl oxygen-convallatoxigenin, 1,3,11,19- tetrem acyl-oxygen
Kombe-Strophanthin, 3,11,19- triacetyl oxygen Kombe-Strophanthins, 3,19- diethyl acyl-oxygen strophanthidol, 3 β, 11 α-diethyl acyl-oxygen poison hair flower
Glycosides, Strophanthin K, strodival, Combetin, K- strophanthus aglycon -3-L- rhamnoside, convallatoxin,
β-arrow exerts sub- glycosides, divaside, 3- [(6'- deoxidation -2', 3'- dimethoxy-D- glucopyranose) oxygroup] -5,14- dihydroxy
Base -19- oxygroup -20 (22)-enol, 3 α, 14 α -3- [(2', 4'- diethyl acyl-oxygen -6'- deoxidation -3'- methoxyl group-D- galactopyranosyl
Sugar) oxygroup] -5,14- dihydroxy -19- oxygroup -20 (22)-enol, 3- [(4'- acetyl oxygen -6'- deoxidation -2', 3'- dimethoxy
Base-D- glucopyranose) oxygroup] -5,14- dihydroxy -19- oxygroup -20 (22)-enol, 3- [6'- oxygen-(6 "-deoxidations -2 ",
3 "-dimethoxy-D- galactopyranoses)-D- glucopyranose] oxygroup } -5,14- dihydroxy -19- oxygroup -20 (22)-enol,
Radix Strophanthi grati, 17 α -3- benzoxy -5,14- dihydroxy -20 (22)-enol -19- carboxylate methyl ester.
Skin hyperplasia disease of the present invention is psoriasis, verruca vulgaris, periungual wart, seborrheic keratosis, verruca plana
Or plantar wart.
Prevention and treatment skin hyperplasia disease medicament of the present invention and method are also within the scope of the present invention, described
Pharmaceutical composition includes the periplogenin and its derivative of the invention and pharmaceutically acceptable carrier of therapeutically effective amount,
The carrier is diluent, excipient, adhesive, filler, burst apart agent and other adjuvants.
Pharmaceutical composition of the present invention can through dilution or directly be used by user using preceding, and preparation can be by
Common processing method preparation known in those skilled in the art.
Pharmaceutical composition of the present invention can be prepared into the pharmaceutical dosage form for being adapted to different way of administration as needed,
In more preferably dosage form be capsule, tablet, emulsion, creme, gelling agent or paste, the pharmaceutical composition contains periplogenin
And its weight content of derivative is 1~99%.
Periplogenin and its derivative of the invention can be by external application and oral two kinds of approach administration, and amount ranges can be with disease
Human feelings condition does corresponding adjustment with the difference of administration route.
Periplogenin and its derivative of the present invention, which pass through, inhibits application on human skin abnormal proliferative cell proliferation, and through thin
Born of the same parents' experiment and zoopery confirm significant effect, and safety is good, are a kind of novel skin hyperplasia disease therapeuticing medicines, have
Good application prospect.
Detailed description of the invention
Fig. 1 is the influence that periplogenin synthesizes HaCaT cell DNA；
Fig. 2 is the histological observation that periplogenin influences psoriasis guinea pig model；A is control group；B is inderal model
Group；C is periplogenin experimental group.
Specific embodiment
The present invention will be further explained with reference to the examples below, as described below, is only to preferable implementation of the invention
Example, not limits the present invention, any person skilled in the art is possibly also with the disclosure above
Technology contents be changed to the equivalent embodiment changed on an equal basis.Without departing from the concept of the present invention, according to the present invention
Technical spirit any simple modification or equivalent variations that following embodiment is made, fall within the scope of protection of the present invention.
The influence of 1 periplogenin of embodiment and its derivative to people's epidermal keratinocytes cambial cell vigor
People's epidermal keratinocytes cambial cell HaCaT cell inoculation is cultivated into 96 orifice plates, cell density is 1.2 × 104
Dosing after a/ml, 12h, drug carry out doubling dilution with 1640 culture mediums containing 3%FBS, and negative group with containing DMSO's
1640 culture mediums of 3%FBS compare, and every group sets 3 multiple holes, and administration volume is 100 holes μ l/；Cell is in 37 DEG C containing 5%CO2
Incubator continues after cultivating 44h, and every hole adds 20 μ l MTT (5mg/ml), continues to cultivate 4h；It inhales and abandons supernatant, 100 μ l are added in every hole
DMSO vibrates 10min in microplate reader, detects the OD value at 570nm, and calculate inhibiting rate, and inhibiting rate=(1- experimental group
Absorbance mean value/control group absorbance mean value) × 100%；Independent experiment in triplicate more than, experimental data is united with SPSS
It counts software and calculates IC50 value.It the results are shown in Table 1, the proliferation table of periplogenin and its derivative 579-1 to 579-23 to HaCaT cell
Reveal with different degrees of inhibiting effect, and derivative 579-24 to 579-27 is without obvious inhibiting effect.
1 periplogenin of table and its derivative measure the IC50 of HaCaT cell
The detection of 2 periplogenin of embodiment and its derivative to subcutaneous connective tissue cytotoxic dosage
Subcutaneous connective tissue cell A9 cell is inoculated in 96 orifice plates, cell density is 1.2 × 104A/ml；Add after 12h
Medicine, drug carry out doubling dilution with the DMEM culture medium containing 3%FBS, and the negative group of DMEM with the 3%FBS containing DMSO is trained
Feeding base compares, and every group sets 3 multiple holes, and administration volume is 100 holes μ l/；Cell continues to cultivate in 37 DEG C of incubators containing 5%CO2
After 44h, every hole adds 20 μ l MTT (5mg/ml), continues to cultivate 4h；It inhales and abandons supernatant, 100 μ l DMSO are added in every hole, in microplate reader
On, 10min is vibrated, the OD value at 570nm is detected；Independent experiment in triplicate more than, experimental data uses SPSS statistical software
IC10 value is calculated, the drug concentration for having 90% or more cell survival is non-toxic or low-toxic dosage.It the results are shown in Table 2, show periploca spium
Aglycon and 579-1 to 579-27 derivative are to subcutaneous connective tissue A9 cell without overt toxicity.
2 periplogenin of table and its derivative measure the IC10 of A9 cell
The influence that 3 periplogenin of embodiment and its derivative synthesize HaCaT cell DNA
In order to further inquire into the influence of periplogenin and its derivative to HaCaT cell Proliferation, we carry out again
BrdU incorporation experiment.HaCaT cell is handled using the periplogenin and its derivative of 2 μ g/ml of final concentration, while being handled with DMSO
Group makees negative control, after dosing acts on different time, after mixing BrdU 6h, by a series of processing, with microplate reader in 450nm
Detect its OD value in place.The result is shown in Figure 1, periplogenin treated HaCaT cell in 12h, for 24 hours, 36h and 48h each period,
Its BrdU incorporation is below DMSO control group, and while handling for 24 hours has just reached extremely significant level, shows that periplogenin can lead to
It crosses and the DNA of HaCaT cell is inhibited to synthesize to inhibit its proliferation.Other derivatives also show similar result.
Influence of 4 periplogenin of embodiment to HaCaT cell cycle
After HaCaT cell is handled 12h with the periplogenin of 2 μ g/ml, culture medium is collected into centrifuge tube, PBS washes one
Time, with 0.25% trypsin digestion cell for a period of time after, discard pancreatin, blow down cell with the culture solution previously collected and be centrifuged receipts
Collect cell；PBS washes one time, again centrifugation cell；Cell, 4 DEG C of fixed 12h are resuspended with 75% ethyl alcohol of ice bath；Centrifugation is heavy
Shallow lake cell, PBS wash one time, again centrifugation cell；0.5ml propidium iodide stain liquid is added in every pipe sample, slowly and fills
Divide and cell precipitation is resuspended, 37 DEG C are protected from light warm bath 30min, and subsequent ice bath is protected from light storage, carry out cell cycle inspection with flow cytometer
It surveys.The results show that control group G1 phase cell proportion is 28.18%, dosing group G1 phase cell apparent increase is 37.95%, as a result
Show that HaCaT cell block in the G1 phase, may be by inhibiting HaCaT cell-cycle arrest cell living by periplogenin
Power.
The research that 5 periplogenin of embodiment acts on cavy psoriasis model
1) preparation of inderal ointment and periplogenin and its derivative ointment
The preparation of inderal (5%) ointment：First by inderal tablet press at powder, weighs and press package insert content
Inderal weight is calculated, later plus on a small quantity dissolved in purified water to paste；Suitable vaseline is weighed, inderal content is made to account for paste
The 5% of total weight；Heated water bath pot, by vaseline and the water-bath together of inderal aqueous solvent, 60 DEG C of water temperature or so；It is molten to vaseline
Change to translucent, the two is slowly mixed together, and is sufficiently stirred, is blended in water bath progress；After mixing, emulsifiable paste is existed
It is placed at room temperature for cooling, is sealed later.
The preparation of periplogenin and its derivative (0.2 ‰) ointment：It first will be after periplogenin and its derivative powder weighing
Add a small amount of dissolved in purified water to paste；Suitable vaseline is weighed, periplogenin and its derivative content is made to account for paste total weight
0.2 ‰；Heated water bath pot, by vaseline and periplogenin and its water-bath together of derivative aqueous solvent, 60 DEG C of water temperature or so；To
Vaseline is melted to translucent, and the two is slowly mixed together, and is sufficiently stirred, and is blended in water bath progress；After mixing,
Emulsifiable paste is being placed at room temperature for cooling, is being sealed later
2) cavy 400g or so adaptive feeding 7 days, pays attention to replenishing vitamins C and fresh vegetables.It is randomly divided into 3
Group, control group, model group and experimental group, every group 10.Control group always with ointment bases smear cavy outer auricle, daily two
It is secondary, continue 30 days.Model group and periplogenin ointment group are smeared outer auricle with inderal (Inderal) ointment and are twice daily held
It is 16 days continuous.Stop at the 17th day it is drug-induced, model group smear ointment bases, experimental group smear periplogenin (0.2 ‰) ointment,
Twice daily, continue 14 days.At the 31st day, excessive anaesthesia puts to death cavy, takes ear cleaning label, is fixed with 10% formaldehyde,
Carry out paraffin section and HE dyeing.
3) each group cavy ear gross morphology changes
As a result, local skin is red and swollen obvious at auricle smearing after inderal ointment 16 days for model group and experimental group smearing, hair
Heat, auricle thickness obviously increase, and are covered with fine silver white scales and obvious, the telangiectasis hyperemia that falls off, psoriasis disease
Disease is obvious.Control group cavy skin of pinna is flat, and telangiectasis is unobvious, and ears are without redness.Give periplogenin ointment
After treatment 14 days, cavy auricle thickness is obviously reduced, and the scales of skin that peel off disappears.
4) each group cavy ear tissue Pathologic changes
As a result as shown in Fig. 2, each group cavy ear tissue sections observation is as it can be seen that model group acanthosis, there is inflammation in mastoid process
Property cellular infiltration, stratum granulosum is thinning or disappears, and trochanterellus extends in rodlike, extends in mastoid process in pestle shape.It is soft to give periplogenin
After cream treatment, parakeratosis mitigates, and cell infiltration is reduced, and 1-2 layers of stratum granulosum occurs in majority, and telangiectasis etc. obviously subtracts
Gently.
The clinical research of 6 periplogenin of embodiment and its derivatives for treatment psoriasis
76 typical psoriatics of symptom are chosen throughout the country, and the clinic for carrying out Chinese medicine composition of the invention is real
It tests.This 76 32 people of patient male, 44 people of women is oldest 68 years old, 16 years old the smallest, and average age 38 years old.
Treatment method：It is treated using periplogenin in embodiment 5 and its derivative ointment, weekly treatment 2 times, 4 weeks
For 1 course for the treatment of, treats and observe curative effect after 1 course for the treatment of, follow-up 4 weeks.
Criterion of therapeutical effect：It is classified according to the symptom situation of change and cardinal symptom of patient.
Recovery from illness：Fash all subsides or recession > 95%.
It is effective：Deflorescence 75%~94%.
Effectively：Deflorescence 31%~74%.
In vain：Deflorescence < 30%.
Treatment results statistics such as table 3：
3 skin hyperplasia disease therapeuticing effect of table
| Gender | Recovery from illness | It is effective | Effectively | In vain | Observe curative effect |
| Male | 20 people | 10 people | 2 people | 0 people | Without recurrence |
| Female | 27 people | 16 people | 1 people | 0 people | Without recurrence |
It is counted by 3 result of table it is found that 47 patient's recoveries from illness, cure rate has reached 61.84%, 26 trouble in 76 patients
Person's symptom is obviously improved, and obvious effective rate has reached 34.21%, and 3 people are effective, and total effective rate is up to 100%, and then carries out tracking sight
It examines and does not occur recurrence status.
Claims (4)
1. periplogenin and its derivative are in preparation for preventing and treating the application in psoriasis, which is characterized in that the thick stick
Willow aglycon and its derivant structure general formula are as follows：
Wherein, R1 is hydroxyl, and R2 is hydrogen, and R3 is methyl, and R4 is hydrogen, and R5 is hydrogen, this compound is periplogenin；
Or R1 is hydroxyl, R2 is hydroxyl, and R3 is hydroxyl, and R4 is hydroxyl, and R5 is hydrogen, this compound is Kombe-Strophanthin；
Or R1 is hydroxyl, R2 is hydrogen, and R3 is hydroxyl, and R4 is hydrogen, and R5 is hydrogen, this compound is 17 α-strophanthidol；
Or R1 is hydroxyl, R2 is hydrogen, and R3 is carboxyl, and R4 is hydrogen, and R5 is hydrogen, this compound is 17 α -3,5,14- trihydroxies -20
(22)-enol -19- carboxylic acid；
Or R1 is acetoxyl group, R2 is hydrogen, and R3 is hydroxyl, and R4 is hydrogen, and R5 is hydrogen, this compound is 17 α -3- acetyl oxygen -5,14,
19- trihydroxy -20 (22)-enol；
Or R1 is acetoxyl group, R2 is hydrogen, and R3 is hydroxyl, and R4 is hydrogen, and R5 is hydrogen, this compound is 3- acetyl oxygen -5,14- dihydroxy
Base -20 (22)-enol；
Or R1 is acetoxyl group, R2 is hydrogen, and R3 is methyl, and R4 is hydrogen, and R5 is hydrogen, this compound is -17 α of 3- acetyl oxygen-poison hair
The sub- glucoside member of japanese bearbind；
Or R1 is acetoxyl group, R2 is acetoxyl group, and R3 is acetoxyl group, and R4 is acetoxyl group, and R5 is hydrogen, this compound is 1,
3,11,19- tetrem acyl-oxygen Kombe-Strophanthin；
Or R1 is acetoxyl group, R2 is hydroxyl, and R3 is acetoxyl group, and R4 is acetoxyl group, and R5 is hydrogen, this compound is 3,11,
19- triacetyl oxygen Kombe-Strophanthin；
Or R1 is acetoxyl group, R2 is hydrogen, and R3 is acetoxyl group, and R4 is hydrogen, and R5 is hydrogen, this compound is 3,19- diethyl acyl-oxygen
Strophanthidol；
Or R1 is acetoxyl group, R2 is hydroxyl, and R3 is hydroxyl, and R4 is acetoxyl group, and R5 is hydrogen, this compound is 3 β, 11 α-two
Acetyl oxygen Kombe-Strophanthin；
Or R1 is 6- methyl -5- hydroxyl -4- methoxyl group pyrans oxygroup, R2 is hydrogen, and R3 is aldehyde radical, and R4 is hydrogen, and R5 is hydrogen, this chemical combination
Object is Strophanthin K；
Or R1 is 6- deoxidation-α-L- sandlwood glycosyloxy, R2 is hydroxyl, and R3 is hydroxyl, and R4 is hydroxyl, and R5 is hydrogen, this compound is
Strodival；
Or R1 is 2,6- deoxidation -3- methoxyl group-β-D- core-own pyrans glycosyloxy, R2 is hydrogen, and R3 is aldehyde radical, and R4 is hydrogen, and R5 is
Hydrogen, this compound are Combetin；
Or R1 is 6- deoxidation-α-L- sandlwood glycosyloxy, R2 is hydrogen, and R3 is aldehyde radical, and R4 is hydrogen, and R5 is hydrogen, this compound is K- poison
The hair aglycon -3-L- rhamnoside of japanese bearbind；
Or R1 is 6- methyl -3,4,5- trihydroxy pyrans oxygroup, R2 is hydrogen, and R3 is aldehyde radical, and R4 is hydrogen, and R5 is hydrogen, this compound
For convallatoxin；
Or R1 is 6- methyl -3,4,5- trihydroxy pyrans oxygroup, R2 is hydrogen, and R3 is aldehyde radical, and R4 is hydrogen, and R5 is hydroxyl, this chemical combination
Object is that β-arrow exerts sub- glycosides；
Or R1 is 6- methyl -3,5- dihydroxy -4- methoxyl group pyrans oxygroup, R2 is hydrogen, and R3 is methyl, and R4 is hydrogen, and R5 is hydrogen, this
Compound is divaside；
Or R1 is 6- deoxidation -2,3- dimethoxy-D- glucopyra glycosyloxy, R2 is hydrogen, and R3 is aldehyde radical, and R4 is hydrogen, and R5 is hydrogen,
This compound is 3- [(6'- deoxidation -2', 3'- dimethoxy-D- glucopyranose) oxygroup] -5,14- dihydroxy -19- oxygroup -
20 (22)-enol；
Or R1 is 2,4- diethyl acyl-oxygen -6- deoxidation -3- methoxyl group-D- galactopyranosyl glycosyloxy, R2 is hydrogen, and R3 is methyl, and R4 is
Hydrogen, R5 are hydrogen, this compound is 3 α, 14 α -3- [(2', 4'- diethyl acyl-oxygen -6'- deoxidation -3'- methoxyl group-D- galactopyranose)
Oxygroup] -5,14- dihydroxy -19- oxygroup -20 (22)-enol；
Or R1 is 4- acetyl oxygen -6- deoxidation -2,3- dimethoxy-D- glucopyra glycosyloxy, R2 is hydrogen, and R3 is aldehyde radical, and R4 is
Hydrogen, R5 are hydrogen, this compound is 3- [(4'- acetyl oxygen -6'- deoxidation -2', 3'- dimethoxy-D- glucopyranose) oxygroup] -
5,14- dihydroxy -19- oxygroup -20 (22)-enol；
Or R1 is 6- oxygen-(6'- deoxidation -2', 3'- dimethoxy-D- galactopyranose)-D- glucopyra glycosyloxy, R2 is hydrogen,
R3 is aldehyde radical, and R4 is hydrogen, and R5 is hydrogen, this compound be 3- [6'- oxygen-(and 6 "-deoxidations -2 ", 3 "-dimethoxy-D- galactopyranosyls
Sugar)-D- glucopyranose] oxygroup } -5,14- dihydroxy -19- oxygroup -20 (22)-enol；
Or R1 is 6- methyl -3,4,5- trihydroxy pyrans oxygroup, R2 is hydroxyl, and R3 and R4 are five yuan of lactones, and R5 is hydrogen, this chemical combination
Object is Radix Strophanthi grati；
Or R1 is benzoyloxy, R2 is hydrogen, and R3 is methoxycarbonyl group, and R4 is hydrogen, and R5 is hydrogen, this compound is 17 α -3- benzoyls
Oxygen -5,14- dihydroxy -20 (22)-enol -19- carboxylate methyl ester.
2. application according to claim 1, it is characterised in that：The periplogenin and its derivative are as preparation prevention and treatment
Application in psoriasis composition.
3. application according to claim 2, it is characterised in that：The pharmaceutical composition be made capsule, tablet, emulsion,
Creme, gelling agent or paste.
4. application according to claim 2, it is characterised in that：The pharmaceutical composition contains periplogenin and its derivative
The weight content of object is 1~99%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510811907.0A CN105343110B (en) | 2015-11-19 | 2015-11-19 | A kind of periplogenin and its derivative are used to prevent and treat the application of skin hyperplasia disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510811907.0A CN105343110B (en) | 2015-11-19 | 2015-11-19 | A kind of periplogenin and its derivative are used to prevent and treat the application of skin hyperplasia disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105343110A CN105343110A (en) | 2016-02-24 |
| CN105343110B true CN105343110B (en) | 2018-11-16 |
Family
ID=55319270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510811907.0A Active CN105343110B (en) | 2015-11-19 | 2015-11-19 | A kind of periplogenin and its derivative are used to prevent and treat the application of skin hyperplasia disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343110B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850847A (en) * | 2006-05-10 | 2006-10-25 | 天津中医药大学 | Method for preparing periplogenin |
-
2015
- 2015-11-19 CN CN201510811907.0A patent/CN105343110B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850847A (en) * | 2006-05-10 | 2006-10-25 | 天津中医药大学 | Method for preparing periplogenin |
Non-Patent Citations (3)
| Title |
|---|
| 杠柳苷元对肥大细胞脱颗粒及释放组胺影响的研究;顾卫等;《中国药房》;20081231;第19卷(第03期);166-168 * |
| 杠柳苷元的抗肿瘤作用研究;韩宇博等;《中国小儿血液与肿瘤杂志》;20080229;第13卷(第01期);1-5 * |
| 香加皮活性成分及其药理作用研究进展;张辉云等;《药学进展》;20131231;第37卷(第09期);449-453 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105343110A (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101862351B (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| AU2021469614A1 (en) | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis | |
| CN103130865B (en) | Matrine, oxymatrine enoxolone double salt and preparation method thereof, purposes | |
| Wang et al. | Diversity of potentially exploitable pharmacological activities of the highly prized edible medicinal fungus Antrodia camphorata | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| US20210353580A1 (en) | Application of chlorogenic acid and compositions thereof in preparation of drugs for treating squamous cell carcinoma | |
| CN109350613B (en) | Curcumin compound preparation for treating cancer | |
| CN101805246B (en) | Urushiol compound and medicinal composition thereof, preparation method and application thereof | |
| CN103908484B (en) | Tripterygium wilfordii plastic for treating rheumatoid arthritis and preparation method thereof | |
| CN108186718A (en) | A kind of gynaecology's spray prevented and inhibit HPV viruse | |
| CN102219772A (en) | Cortex pseudolaricis acid complex with bioactivity and preparation method thereof | |
| CN104800216B (en) | The application of Nitidine Chloride and its derivative in preparation prevention and treatment dermatosis treating medicine | |
| CN105343110B (en) | A kind of periplogenin and its derivative are used to prevent and treat the application of skin hyperplasia disease | |
| CN103735653A (en) | Traditional Chinese medicine extract with anti-tumor activity as well as preparation method and use thereof | |
| CN101926844A (en) | Stellera chamaejasme L extract and anti-tumor action thereof | |
| CN105535003A (en) | Uses of calenduloside E in preparation of anti-tumor medicines | |
| CN102389559A (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN102028780A (en) | Novel application of flavonoid of rosa roxburghii tratt to ionizing radiation protection | |
| CN105902561A (en) | Application of Gracilariopsis lemaneiformis polysaccharide as antitumor chemotherapy drug synergist and antitumor drug | |
| CN104997787A (en) | Application of glycyrrhetinic acid in preparation of anti-radiation product | |
| CN110403924A (en) | A kind of pharmaceutical composition and preparation method thereof for treating cutaneous melanoma | |
| CN101940585B (en) | Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof | |
| CN110464755A (en) | A kind of Chinese medicine composition tablet for treating acute pyelonephritis | |
| AU2021106930A4 (en) | Use of epimedium-derived flavonoid glycoside in preparation of medicine for treating melanoma | |
| CN103169693A (en) | Application of wogonin derivant in preparation of drug for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |